Search

Your search keyword '"Martinez, Felipe"' showing total 60 results

Search Constraints

Start Over You searched for: Author "Martinez, Felipe" Remove constraint Author: "Martinez, Felipe" Publisher elsevier inc. Remove constraint Publisher: elsevier inc.
60 results on '"Martinez, Felipe"'

Search Results

1. Dapagliflozin and Timing of Prior Heart Failure Hospitalization: A Patient-Level Meta-Analysis of DAPA-HF and DELIVER

2. Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial

3. Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF: The DELIVER Trial

5. Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER

6. Gut-liver axis calibrates intestinal stem cell fitness

7. Effects of Dapagliflozin in Patients in Asia: A Post Hoc Subgroup Analysis From the DELIVER Trial

8. Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function

9. Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

10. Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status

12. The first Miocene fossils from coastal woodlands in the southern East African Rift

13. Operational challenges and mitigation measures during the COVID-19 pandemic–Lessons from DELIVER

15. Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum

16. IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HF

19. Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

21. Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction

22. Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction

23. Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction

24. Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HF

26. Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF

27. Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial

29. Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction

32. Incidence and Outcomes of Pneumonia in Patients With Heart Failure

33. Effects of a Novel Nitroxyl Donor in Acute Heart Failure: The STAND-UP AHF Study

36. Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial

37. Sex Differences in Heart Failure With Improved Ejection Fraction: The DELIVER Trial

39. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial

41. A Polypill Strategy to Improve Adherence: Results From the FOCUS Project

46. SYMPTOM-PROMPTED, SELF-ADMINISTERED INTRANASAL ETRIPAMIL FOR TERMINATION OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA IN THE RAPID STUDY: RELATIONSHIP AMONG ETRIPAMIL-INDUCED REDUCTION IN TACHYCARDIA RATES, CONVERSION TO SINUS RHYTHM, AND IMPROVEMENT IN PATIENT SYMPTOMS

47. DAPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE ACROSS A RANGE OF LEFT VENTRICULAR HYPERTROPHY IN THE DELIVER TRIAL

48. THE EFFECT OF DAPAGLIFLOZIN ON DAYS OF FULL HEALTH LOST DUE TO DEATH, HOSPITALIZATION, AND IMPAIRED WELL-BEING IN DAPA-HF

50. GROWTH DIFFERENTIATION FACTOR-15, CLINICAL OUTCOMES, AND THE EFFECT OF DAPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION: INSIGHTS FROM THE DAPA-HF TRIAL

Catalog

Books, media, physical & digital resources